Compare INHD & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INHD | CMMB |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 9.1M |
| IPO Year | 2023 | 2023 |
| Metric | INHD | CMMB |
|---|---|---|
| Price | $1.03 | $1.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 157.6K | 74.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.61 | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $2,846,250.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $45.75 |
| Revenue Growth | ★ 221.43 | N/A |
| 52 Week Low | $0.06 | $0.87 |
| 52 Week High | $15.90 | $3.86 |
| Indicator | INHD | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 42.70 | 56.77 |
| Support Level | $1.01 | $1.48 |
| Resistance Level | $1.17 | $2.80 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 17.61 | 78.46 |
Inno Holdings Inc is a building technology company with a mission to transform the construction industry with its proprietary cold-formed steel-framing technology and other innovations. It is a manufacturer of cold-formed-steel members and prefabricated homes. It offers a full range of services required to transform raw materials into precise steel framing products and prefabricated homes. The company sells these finished products either to businesses or directly to customers. The finished products and cold-formed-steel members are used in a variety of building types, including residential, commercial, industrial and infrastructure.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.